^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Solid Tumor
    Drug:MRTX1257 (KRAS inhibitor) +
    ifebemtinib (IN10018) (FAK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2020
    Title:

    Abstract LB-021: Focal adhesive kinase inhibitor IN10018 sensitizes KRAS mutant cancer and overcomes drug resistance of KRAS G12C inhibition

    Published date:
    05/15/2020
    Excerpt:
    IN10018 in combination with either AMG510 or MRTX1257 showed better effects in killing KRAS G12C cancer cells than each single treatment….Our results indicate that KRAS G12C cancer patients can be better treated by the combination of IN10018 with KRAS G12C inhibitor.
    DOI:
    10.1158/1538-7445.AM2020-LB-021